Trial
NCT04381052
Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Columbia University
Collaborators
NYU Langone Health; CSL Behring
Condition
COVID-19
Intervention
Clazakizumab
Why stopped
Study terminated due to poor enrollment. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-04-08